IP Library Granted Patent US 9,447,169
Granted Patent B2
US 9,447,169 · App. 13/411,324 · Granted Sep 20, 2016

Flowable collagen-based hemostat and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,447,169
App. No.
13/411,324
Granted
Sep 20, 2016
Kind
B2
Abstract

The invention relates to hemostatic compositions and methods for promoting hemostasis. The invention also relates to hemostatic compositions and methods for promoting wound healing. In various embodiments, the hemostatic compositions comprise crosslinkable collagen molecules having a porosity controlled by the ratio of weight percent collagen solids to weight percent crosslinker when crosslinking the collagen. In other embodiments, the hemostatic compositions comprise crosslinkable collagen molecules having a porosity controlled by the temperature and rate of freezing when drying the composition during fabrication. In some embodiments, the compositions contain additional agents, including biological agents.

Claims (29)

1. A hemostatic composition consisting essentially of crosslinked collagen scaffold reconstituted in a physiologically acceptable liquid vehicle,

wherein the composition does not contain thrombin;

wherein the composition is flowable and has no residual amount of a crosslinker;

wherein concentration of the crosslinked collagen is from 50-250 mg/mL;

wherein the crosslinked collagen scaffold, prior to reconstitution, has a porosity greater than 50% and a surface area of between 0.5 to 30 m 2 /g; and

wherein the composition has a percent swelling of between 0% to 20% within 10 minutes.

2. The hemostatic composition of claim 1 , wherein the crosslinked collagen scaffold includes at least one material structure from the group consisting of fibers, ribbons, ropes and sheets.

3. The hemostatic composition of claim 2 , wherein the number of structures is controlled by the ratio of percent collagen solids to percent crosslinker when crosslinking the collagen.

4. The hemostatic composition of claim 2 , wherein the number of structures is controlled by the collagen concentration prior to freezing the collagen.

5. The hemostatic composition of claim 2 , wherein the number of structures is controlled by the temperature and rate of freezing when the collagen is lyophilized.

6. The hemostatic composition of claim 1 , wherein the collagen is microfibrillar collagen.

7. The hemostatic composition of claim 1 , wherein the collagen is fibrillar collagen.

8. The hemostatic composition of claim 1 , wherein the liquid vehicle is water, saline, calcium chloride or a combination thereof.

9. The hemostatic composition of claim 8 , wherein the composition can be dispensed from a syringe having at least a 1.6 mm opening.

10. The hemostatic composition of claim 1 , wherein the composition has a porosity controlled by the temperature and rate of freezing used to manufacture the composition.

11. The hemostatic composition of claim 9 , wherein the flowability is controlled by the presence of at least one material structure from the group consisting of fibers, ribbons, ropes and sheets.

12. A method of promoting hemostasis at a bleeding site comprising applying the hemostatic composition of claim 1 to the bleeding site.

13. The hemostatic composition of claim 1 , wherein the concentration of the crosslinked collagen is from 100-200 mg/mL.

14. A hemostatic composition consisting essentially of crosslinked collagen scaffold and thrombin reconstituted in a physiologically acceptable liquid vehicle,

wherein the composition is flowable and has no residual amount of a crosslinker;

wherein concentration of the crosslinked collagen is from 50-250 mg/mL;

wherein the crosslinked collagen scaffold, prior to reconstitution, has a porosity greater than 50% and a surface area of between 0.5 to 30 m 2 /g;

and wherein the composition has a percent swelling of between 0% to 20% within 10 minutes.

15. The hemostatic composition of claim 14 , wherein the concentration of the crosslinked collagen is from 100-200 mg/mL.

16. The hemostatic composition of claim 14 , wherein the crosslinked collagen scaffold includes at least one material structure from the group consisting of fibers, ribbons, ropes and sheets.

17. The hemostatic composition of claim 14 , wherein the collagen is microfibrillar collagen.

18. The hemostatic composition of claim 14 , wherein the collagen is fibrillar collagen.

19. The hemostatic composition of claim 14 , wherein the liquid vehicle is water, saline, calcium chloride or a combination thereof.

20. The hemostatic composition of claim 14 , wherein the composition can be dispensed from a syringe having at least a 1.6 mm opening.

Assignments (6)
CHANGE OF ADDRESS Recorded Dec 18, 2024
From: STRYKER CORPORATION
To: STRYKER CORPORATION
Reel/Frame 069737/0184 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2023
From: ORTHOVITA, INC.
To: STRYKER CORPORATION
Reel/Frame 065735/0360 →
CONFIDENTIALITY AND NON-DISCLOSURE AGREEMENT/ EMPLOYMENT AGREEMENT Recorded Jun 26, 2013
From: RAYNOR, JENNY E.
To: ORTHOVITA, INC.
Reel/Frame 030741/0140 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2013
From: DARMOC, MARISSA M.; BROWN, LAUREN S.
To: ORTHOVITA, INC.
Reel/Frame 030741/0147 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2012
From: DARMOC, MARISSA M.; BROWN, LAUREN S.; RAYNOR, JENNY E.
To: ORTHOVITA, INC.
Reel/Frame 029450/0927 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2012
From: CHOU, ALICE; COHEN, ABIGAIL
To: ORTHOVITA, INC.
Reel/Frame 028250/0398 →